📊 CSBR Key Takeaways
Is Champions Oncology, Inc.. (CSBR) a Good Investment?
Champions Oncology shows concerning financial deterioration with negative operating cash flow of -2.5M and free cash flow of -2.8M despite 13.5% revenue growth, indicating the company is burning cash and unable to convert sales into profits. The company is unprofitable with a -1.1% net margin and negative ROE of -11.9%, while maintaining a precarious liquidity position with a current ratio of 0.98x that leaves minimal margin for error.
Champions Oncology is showing decent top-line growth and has materially improved earnings versus the prior year, but the business still remains unprofitable with negative operating and free cash flow. The combination of sub-1.0 liquidity, thin equity, and continued cash burn limits financial flexibility, so the fundamentals remain weak until sustained profitability and cash generation are established.
Why Buy Champions Oncology, Inc.. Stock? CSBR Key Strengths
- Revenue growth of 13.5% YoY demonstrates demand for services
- Cash position of 7.1M provides near-term operational runway
- Low debt burden with 0.00x debt-to-equity ratio reduces financial risk
- Revenue grew 13.5% year over year, indicating continued demand for the company's services
- Net loss and diluted EPS improved significantly year over year, suggesting operating performance is moving toward breakeven
- The balance sheet carries no meaningful debt, reducing solvency risk from leverage
CSBR Stock Risks: Champions Oncology, Inc.. Investment Risks
- Negative operating cash flow of -2.5M indicates unsustainable cash burn despite positive revenue growth
- Current ratio of 0.98x signals liquidity pressure with current liabilities exceeding current assets
- Persistent unprofitability with operating margin of -1.4% and net margin of -1.1% raises questions about business model viability
- Free cash flow margin of -6.1% shows company is consuming capital to generate each dollar of revenue
- Stockholders' equity of only 4.3M on total assets of 28.4M indicates thin equity cushion relative to liabilities
- Operating margin and net margin remain negative, showing the business has not yet achieved durable profitability
- Operating cash flow and free cash flow are both negative, which raises concern about the quality of earnings and internal funding capacity
- Current and quick ratios of 0.98x and only $4.28M of equity indicate tight liquidity and limited balance-sheet cushion
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Gross margin expansion and operating leverage as revenue scales
- Current ratio maintenance above 1.0x to ensure adequate liquidity
- Net income improvement trajectory and timeline to sustained profitability
- Operating cash flow and free cash flow trend
- Operating margin progression toward sustained profitability
Champions Oncology, Inc.. (CSBR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CSBR Profit Margin, ROE & Profitability Analysis
CSBR vs Healthcare Sector: How Champions Oncology, Inc.. Compares
How Champions Oncology, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Champions Oncology, Inc.. Stock Overvalued? CSBR Valuation Analysis 2026
Based on fundamental analysis, Champions Oncology, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Champions Oncology, Inc.. Balance Sheet: CSBR Debt, Cash & Liquidity
CSBR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Champions Oncology, Inc..'s revenue has grown significantly by 39% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
CSBR Revenue Growth, EPS Growth & YoY Performance
CSBR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $16.6M | -$279.0K | $-0.02 |
| Q2 2026 | $13.5M | -$169.0K | $-0.01 |
| Q1 2026 | $14.0M | -$436.0K | $-0.03 |
| Q3 2025 | $12.0M | $728.0K | $-0.19 |
| Q2 2025 | $11.6M | $728.0K | $0.05 |
| Q1 2025 | $12.6M | $1.3M | $0.09 |
| Q3 2024 | $12.0M | -$16.0K | $-0.18 |
| Q2 2024 | $11.6M | -$16.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Champions Oncology, Inc.. Dividends, Buybacks & Capital Allocation
CSBR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Champions Oncology, Inc.. (CIK: 0000771856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CSBR
What is the AI rating for CSBR?
Champions Oncology, Inc.. (CSBR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CSBR's key strengths?
Claude: Revenue growth of 13.5% YoY demonstrates demand for services. Cash position of 7.1M provides near-term operational runway. ChatGPT: Revenue grew 13.5% year over year, indicating continued demand for the company's services. Net loss and diluted EPS improved significantly year over year, suggesting operating performance is moving toward breakeven.
What are the risks of investing in CSBR?
Claude: Negative operating cash flow of -2.5M indicates unsustainable cash burn despite positive revenue growth. Current ratio of 0.98x signals liquidity pressure with current liabilities exceeding current assets. ChatGPT: Operating margin and net margin remain negative, showing the business has not yet achieved durable profitability. Operating cash flow and free cash flow are both negative, which raises concern about the quality of earnings and internal funding capacity.
What is CSBR's revenue and growth?
Champions Oncology, Inc.. reported revenue of $45.6M.
Does CSBR pay dividends?
Champions Oncology, Inc.. does not currently pay dividends.
Where can I find CSBR SEC filings?
Official SEC filings for Champions Oncology, Inc.. (CIK: 0000771856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CSBR's EPS?
Champions Oncology, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CSBR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Champions Oncology, Inc.. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CSBR stock overvalued or undervalued?
Valuation metrics for CSBR: ROE of -11.9% (sector avg: 15%), net margin of -1.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CSBR stock in 2026?
Our dual AI analysis gives Champions Oncology, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CSBR's free cash flow?
Champions Oncology, Inc..'s operating cash flow is $-2.5M, with capital expenditures of $325.0K. FCF margin is -6.1%.
How does CSBR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.1% (avg: 12%), ROE -11.9% (avg: 15%), current ratio 0.98 (avg: 2).